Abstract

Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy.

REFERENCES

1.
Teras
LR
,
DeSantis
CE
,
Cerhan
JR
,
Morton
LM
,
Jemal
A
,
Flowers
CR
.
2016 US lymphoid malignancy statistics by World Health Organization subtypes
.
CA Cancer J Clin
.
2016
;
66
(
6
):
443
-
459
.
2.
Maurer
MJ
,
Bachy
E
,
Ghesquières
H
, et al
.
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
.
Am J Hematol
.
2016
;
91
(
11
):
1096
-
1101
.
3.
Tan
D
,
Horning
SJ
,
Hoppe
RT
, et al
.
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
.
Blood
.
2013
;
122
(
6
):
981
-
987
.
4.
Marcus
R
,
Imrie
K
,
Belch
A
, et al
.
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
.
Blood
.
2005
;
105
(
4
):
1417
-
1423
.
5.
Salles
G
,
Mounier
N
,
de Guibert
S
, et al
.
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
.
Blood
.
2008
;
112
(
13
):
4824
-
4831
.
6.
Herold
M
,
Haas
A
,
Srock
S
, et al;
East German Study Group Hematology and Oncology Study
.
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study
.
J Clin Oncol
.
2007
;
25
(
15
):
1986
-
1992
.
7.
Gribben
JG
,
Fowler
N
,
Morschhauser
F
.
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
.
J Clin Oncol
.
2015
;
33
(
25
):
2803
-
2811
.
8.
Ramsay
AG
,
Clear
AJ
,
Kelly
G
, et al
.
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
.
Blood
.
2009
;
114
(
21
):
4713
-
4720
.
9.
Zucca
E
,
Rondeau
S
,
Vanazzi
A
, et al;
Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group
.
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
.
Blood
.
2019
;
134
(
4
):
353
-
362
.
10.
Fowler
NH
,
Davis
RE
,
Rawal
S
, et al
.
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
.
Lancet Oncol
.
2014
;
15
(
12
):
1311
-
1318
.
11.
Martin
P
,
Jung
SH
,
Pitcher
B
, et al
.
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)
.
Ann Oncol
.
2017
;
28
(
11
):
2806
-
2812
.
12.
Salles
G
,
Seymour
JF
,
Offner
F
, et al
.
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
.
Lancet
.
2011
;
377
(
9759
):
42
-
51
.
13.
Morschhauser
F
,
Fowler
NH
,
Feugier
P
, et al;
RELEVANCE Trial Investigators
.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
.
N Engl J Med
.
2018
;
379
(
10
):
934
-
947
.
14.
Shi
Q
,
Flowers
CR
,
Hiddemann
W
, et al
.
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
.
J Clin Oncol
.
2017
;
35
(
5
):
552
-
560
.
15.
Witzig
TE
,
Wiernik
PH
,
Moore
T
, et al
.
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma
.
J Clin Oncol
.
2009
;
27
(
32
):
5404
-
5409
.
16.
Chong
EA
,
Ahmadi
T
,
Aqui
NA
, et al
.
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
.
Clin Cancer Res
.
2015
;
21
(
8
):
1835
-
1842
.
17.
Leonard
JP
,
Jung
SH
,
Johnson
J
, et al
.
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
.
J Clin Oncol
.
2015
;
33
(
31
):
3635
-
3640
.
18.
Leonard
JP
,
Trneny
M
,
Izutsu
K
, et al;
AUGMENT Trial Investigators
.
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
.
J Clin Oncol
.
2019
;
37
(
14
):
1188
-
1199
.
19.
Andorsky
DJ
,
Coleman
M
,
Yacoub
A
, et al
.
MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma [abstract]
.
J Clin Oncol
.
2019
;
37
(
suppl 15
). Abstract 7513.
20.
Ujjani
CS
,
Jung
SH
,
Pitcher
B
, et al
.
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103
.
Blood
.
2016
;
128
(
21
):
2510
-
2516
.
21.
Smith
SM
,
Pitcher
BN
,
Jung
SH
, et al
.
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
.
Lancet Haematol
.
2017
;
4
(
4
):
e176
-
e182
.
22.
Solal-Céligny
P
,
Roy
P
,
Colombat
P
, et al
.
Follicular lymphoma international prognostic index
.
Blood
.
2004
;
104
(
5
):
1258
-
1265
.
You do not currently have access to this content.

Sign in via your Institution

Sign In